Benitec Q3 net loss $0.24/shr, cash $184.8M; BB-301 clinical progress continues

Benitec Biopharma Inc.

2026-Q3 EPS reported -$0.72

Net loss $11.9M ($0.24/shr) vs $14.5M ($0.38/shr) in prior year quarter; total expenses $13.6M.
Cash and equivalents $184.8M, well-capitalized to advance BB-301 through pivotal study.
Cohort 1 low-dose BB-301 shows durable responses at 12-24 months; Cohort 2 high dose safely treating patients.
Oral presentation at ASGCT 2026 on May 15; FDA engagement mid-year to formalize pivotal study design.
Updated BB-301 interim results expected 2H-2026; no treatment-related severe adverse events observed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2026 results: net income Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and, EPS $(0.24) per basic and diluted share.

Period: third fiscal quarter ended March 31, 2026
Net income: Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and
EPS: $(0.24) per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and diluted share

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.